Skip to main content
SpringerLink
Log in

The Way to Clinical Application of Human Pluripotent Stem Cells

  • Chapter
Gene Therapy and Cell Therapy Through the Liver

  • 1124 Accesses

Abstract

Human embryonic stem (ES) cells are expected to be a resource for regenerative medicine because of their pluripotency and ability to self-renew. In 2007, human-induced pluripotent stem (iPS) cells were generated from somatic cells by introducing small sets of transcription factors, raising further hopes of clinical applications of pluripotent stem cells. Today, several promising projects using these cells have been launched.

It is necessary to consider regulatory issues regarding iPS/ES cell applications from at least three points of view. First, researchers should pay serious attention to the rights of donors, particularly privacy protection and decision-making in terms of the use of pluripotent stem cells derived from “the pieces of their own body.” Second, for iPS/ES cell-based transplantation therapy, patients with target diseases should be protected from the risks of undergoing and not undergoing such treatments. Third, the dignity of life should be carefully considered.

In Japan, there used to be two regulatory frameworks for the clinical application of pluripotent stem cells with respect to clinical studies: the provisions of the Pharmaceutical Affairs Law and Medical Practitioners’ Act. Recently, relevant regulatory reforms were made to promote and more rationally regulate the field of regenerative medicine.

In order to expedite the realization of clinical applications of pluripotent stem cells, researchers must follow established guidelines as well as precisely grasp the current trends in corresponding regulations and technologies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–7.

    Article  CAS  PubMed  Google Scholar 

  2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.

    Article  CAS  PubMed  Google Scholar 

  3. Japan Science and Technology Agency, http://www.jst.go.jp/saisei-nw/highway/

  4. Ministry of Health, Labour and Welfare, http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000066236.pdf. Accessed 3 Mar 2015

  5. Kamao H, Mandai M, Okamoto S, Sakai N, Suga A, Sugita S, et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep. 2014;2(2):205–18.

    Article  CAS  Google Scholar 

  6. 365 days: Nature’s 10 Ten people who mattered this year. Nature. 2014;516, 311–319. doi:10.1038/516311a

  7. Kikuchi T, Morizane A, Doi D, Onoe H, Hayashi T, Kawasaki T, et al. Survival of human induced pluripotent stem cell–derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson’s disease. J Parkinsons Disease. 2011;1(4):395–412.

    CAS  Google Scholar 

  8. Kobayashi Y, Okada Y, Itakura G, Iwai H, Nishimura S, Yasuda A, et al. Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS One. 2012;7(12), e52787. doi:10.1371/journal.pone.0052787. Epub 2012 Dec 27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K, et al. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell. 2014;14(4):535–48. doi:10.1016/j.stem.2014.01.

    Article  CAS  PubMed  Google Scholar 

  10. Kawamura M, Miyagawa S, Miki K, Saito A, Fukushima S, Higuchi T, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation. 2012;126(11 Suppl 1):S29–37.

    Article  CAS  PubMed  Google Scholar 

  11. Hemmi N, Tohyama S, Nakajima K, Kanazawa H, Suzuki T, Hattori F, et al. A massive suspension culture system with metabolic purification for human pluripotent stem cell-derived cardiomyocytes. Stem Cells Transl Med. 2014;3(12):1473–83. doi:10.5966/sctm.2014-0072. Epub 2014 Oct 29.

    Article  CAS  PubMed  Google Scholar 

  12. Hayashi R, Ishikawa Y, Ito M, Kageyama T, Takashiba K, Fujioka T, et al. Generation of corneal epithelial cells from induced pluripotent stem cells derived from human dermal fibroblast and corneal limbal epithelium. PLoS One. 2012;7(9), e45435. doi:10.1371/journal.pone.0045435. Epub 2012 Sep 24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Yoshida S, Yasuda M, Miyashita H, Ogawa Y, Yoshida T, Matsuzaki Y, et al. Generation of stratified squamous epithelial progenitor cells from mouse induced pluripotent stem cells. PLoS One. 2011;6(12), e28856. doi:10.1371/journal.pone.0028856. Epub 2011 Dec 9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013;499(7459):481–4. doi:10.1038/nature12271. Epub 2013 Jul 3.

    Article  CAS  PubMed  Google Scholar 

  15. Nakamura N, Saeki K, Mitsumoto M, Matsuyama S, Nishio M, Saeki K, et al. Feeder-free and serum-free production of hepatocytes, cholangiocytes, and their proliferating progenitors from human pluripotent stem cells: application to liver-specific functional and cytotoxic assays. Cell Reprogram. 2012;14(2):171–85. doi:10.1089/cell.2011.0064. Epub 2012 Mar 2.

    CAS  PubMed  Google Scholar 

  16. Hayakawa T, Aoi T, Umezaw A, Ozawa K, Sato Y, Sawa Y, et al. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem (−like) cells. Regener Ther 1 (in press).

    Google Scholar 

  17. Hayakawa T, Aoi T, Umezaw A, Ozawa K, Sato Y, Sawa Y, et al. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogenic human induced pluripotent stem (−like) cells. Regener Ther 1 (in press).

    Google Scholar 

  18. Hayakawa T, Aoi T, Umezaw A, Ozawa K, Sato Y, Sawa Y, et al. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of human embryonic stem (−like) cells. Regener Ther 1 (in press).

    Google Scholar 

  19. Hayakawa T, Aoi T, Umezaw A, Ozawa K, Sato Y, Sawa Y, et al. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human somatic stem cells. Regener Ther 1 (in press).

    Google Scholar 

  20. Hayakawa T, Aoi T, Umezaw A, Ozawa K, Sato Y, Sawa Y, et al. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogenic human somatic stem cells. Regener Ther 1 (in press).

    Google Scholar 

  21. Ministry of Health, Labour and Welfare, http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000063418.pdf. Accessed 3 Mar 2015

  22. Ministry of Health, Labour and Welfare, http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000030847.pdf. Accessed 3 Mar 2015.

  23. Ministry of Internal Affairs and Communications, http://law.e-gov.go.jp/htmldata/S35/S35HO145.html. Accessed 3 Mar 2015.

  24. Ministry of Internal Affairs and Communications, http://law.e-gov.go.jp/htmldata/H26/H26F19001000093.html. Accessed 3 Mar 2015.

  25. Pharmaceuticals and Medical Devices Agency, Japan, http://www.pmda.go.jp/english/about/pdf/profile_of_services.pdf. Accessed 3 Mar 2015.

  26. Pharmaceuticals and Medical Devices Agency, Japan, http://www.pmda.go.jp/english/scienceboard/scienceboard/pdf/20130820/file01.pdf. Accessed 3 Mar 2015.

  27. The International Stem Cell Forum, http://www.stem-cell-forum.net/. Accessed 3 Mar 2015.

  28. International Stem Cell Banking Initiative. Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes. Stem Cell Rev. 2009;5(4):301–14. doi:10.1007/s12015-009-9085-x.

    Article  Google Scholar 

  29. Andrews P, Baker D, Benvinisty N, Miranda B, Bruce K, Brüstle O, et al. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen Med. 2015;10(2 Suppl):1–44. doi:10.2217/rme.14.93.

    Article  CAS  PubMed  Google Scholar 

  30. International Alliance for Biological Standardization, http://www.iabs.org/. Accessed 3 Mar 2015

Download references

Author information

Authors and Affiliations

  1. Department of iPS cell Applications, Graduate School of Medicine, Kobe University, 7-5-1 Kusunoki-cyo, Chuo-ku, Kobe, Hyogo, 650-0017, Japan

    Takashi Aoi

Authors
  1. Takashi Aoi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takashi Aoi .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University , Niigata, Niigata, Japan

    Shuji Terai

  2. Department of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University, Niigata, Niigata, Japan

    Takeshi Suda

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Aoi, T. (2016). The Way to Clinical Application of Human Pluripotent Stem Cells. In: Terai, S., Suda, T. (eds) Gene Therapy and Cell Therapy Through the Liver. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55666-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55666-4_9

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55665-7

  • Online ISBN: 978-4-431-55666-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation